ANKRA2

Across TCGA pan-cancer cohorts, ANKRA2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ANKRA2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ANKRA2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKRA2 expression acts as an unfavorable survival marker.

OV and BLCA are the cancer types where ANKRA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.215	0.541	.027	18	view →
BLCA	OS	Median	All	0.141	0.687	.003	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ANKRA2–OV (DFS)

Open the OV breakdown →